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A B S T R A C T
Background: Gait instability is a major fall-risk factor in patients with chronic obstructive pulmonary disease
(COPD). Clinical gait analysis is a reliable tool to predict fall onsets. However, controversy still exists on gait
impairments associated with COPD.
Research question: Thus, the aims of this review were to evaluate the current understanding of spatiotemporal,
kinematic and kinetic gait features in patients with COPD.
Methods: In line with PRISMA guidelines, a systematic literature search was performed throughout Web of Sci-
ence, PubMed Medline, Scopus, PEDro and Scielo databases. We considered observational cross-sectional studies
evaluating gait features in patients with COPD as their primary outcome. Risk of bias and applicability of these
papers were assessed according to the QUADAS-2 tool.
Results: Seven articles, cross-sectional studies published from 2011 to 2017, met the inclusion criteria. Sample
size of patients with COPD ranged 14–196 (mean age range: 64–75 years). The main reported gait abnormalities
were reduced step length and cadence, and altered variability of spatiotemporal parameters. Only subtle biome-
chanical changes were reported at the ankle level.
Significance: A convincing mechanistic link between such gait impairments and falls in patients with COPD is still
lacking. The paucity of studies, small sample sizes, gender and disease status pooling were the main risk of bi-
ases affecting the results uncertainty. Two research directions emerged: stricter cohorts characterization in terms
of COPD phenotype and longitudinal studies. Quantitative assessment of gait would identify abnormalities and
sensorimotor postural deficiencies that in turn may lead to better falling prevention strategies in COPD.
1. Introduction
Chronic obstructive pulmonary disease (COPD) causes over three
million deaths annually, with a global prevalence of 8–15% [1]. COPD
is a lungs disease characterized by chronic airflow obstruction due to
structural abnormalities of the airways (bronchitis and bronchiolitis),
associated with an inflammatory reaction of the alveoli and pulmonary
vessels [2]. Treatment of COPD has traditionally focused on lung func-
tion. The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
classifies patients according to the value of expired volume in
1s (Forced Expiratory Volume in 1s or FEV1). According to GOLD, stage
1 corresponds to FEV1≥80% of predicted; stage 2 50% ≤FEV1<80% of
predicted; stage 3 30% ≤FEV1<50% of predicted; stage 4, FEV1<30%
of predicted, while the FEV1/FVC (Forced Vital Capacity) ratio is <70%
in all stages [3]. However, COPD is also accompanied by several ex-
trapulmonary chronic alterations that affect body systems, including
weight loss, cardiovascular disease, metabolic disturbances, muscles
weakness and atrophy, osteoporosis [4,5]. These persistent illnesses re-
sult in a multimorbidity condition that significantly impairs patients’
health increasing the effect of common risk factors like smoking, diet,
alcohol, physical inactivity and aging [3].
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In particular, as skeletal muscle weakness leads to limited mobil-
ity, motor incoordination and functional limitations, individuals with
COPD present postural control impairment with respect to age-matched
healthy controls [6–9]. As a consequence of such balance deficits, pa-
tients with COPD fall frequently [10–13]. This is a major health con-
cern, since falling represents one of the main causes of pain, inactivity,
disability, loss of functional independence and death in the elderly [14].
Falls induce a downward spiral of worsening frailty and loss of mobility
[15]. Despite the causes of falls are multifactorial, the majority of them
happen during walking [16]. A poor gait function is therefore one of the
main risk of falls and a strong risk factor of death [17]. COPD may nega-
tively impact on gait as systemic complications affect the cardiovascular
and musculoskeletal system.
Gait tests like the 6-min walking test (6MWT) or the shuttle walk test
are commonly adopted in clinical practice to evaluate functional perfor-
mance and status [3,18]. These tests are simple, inexpensive and clini-
cally relevant screening tools to assess patients with COPD for exercise
capacity. Gait speed also reflects global well-being, captures multisys-
temic effects of disease severity [19], it is related to the risk of hospital-
isation and can be used to predict survival [20].
Although walking tests and gait speed measure the overall functional
status of the patients, they cannot provide information about the gait
patterns, nor on the biomechanical effects of impaired postural control
during gait. Gait changes are often too subtle to be detected only by
clinical observations, and clinical gait analysis may be the best tool to
predict fall onsets [12]. Thus, the assessment of kinematic and kinetic
gait parameters enables to detect and qualify specific abnormalities and
sudden sensorimotor postural deficiencies in patients with COPD, and in
turn can contribute to prevent the consequences of falls [7].
To date, no systematic review has summarised the literature regard-
ing quantitative gait abnormalities in patients with COPD. Thus, the
purposes of this study are: (i) to evaluate the current understanding
of spatiotemporal, kinematic and kinetic gait features in patients with
COPD, and (ii) to identify relevant gaps in the actual body of knowl-
edge.
2. Methods
2.1. Search strategy
A systematic literature search was undertaken in September 2017
on the following electronic databases: Web of Science (from 1985),
PubMed MEDLINE (from 1985), Scopus (no time limit), Mendeley (from
1990), PEDro (from 1985), Scielo (no time limit). Customised queries
including the following keywords and Boolean logic with AND/OR op-
erators were entered in the search engines: “COPD”, “chronic obstruc-
tive pulmonary disease”, (“gait” OR “gait analysis” OR “locomotion”).
The search was limited to full original articles written in English. Bibli-
ographies of identified papers and relevant conference proceedings were
hand searched for supplemental relevant items, as well as Authors’ per-
sonal collection.
2.2. Eligibility criteria and study selection
Observational cross-sectional studies involving patients clinically di-
agnosed with COPD were included. We considered any functional eval-
uation regarding the assessment of gait mechanics in patients with
COPD, including (but not restricted to) 6MWT and walking trials. Pa-
pers were included that evaluated gait features in patients with COPD
as their primary outcome, in terms of spatiotemporal, kinematics and/
or kinetic parameters. Case series, i.e. studies neither analysing a con
trol group nor referring to a matched healthy population, were not in-
cluded. Studies without diagnostic criteria for COPD, or based solely
on walking distance/speed or qualitative assessment, plethysmography,
electromyography, activity monitors or questionnaires were also ex-
cluded.
By applying these inclusion and exclusion criteria, two reviewers
(DB and MZ) independently screened titles and abstracts of the identi-
fied records and took decision about items retention in a blinded man-
ner. Any disagreement between the examiners was resolved by a techni-
cal discussion involving a third reviewer (MG).
2.3. Evaluation of the quality of the included studies
A standardised data extraction and appraisal form was constructed
to collect the key features of each study. In particular, before the eval-
uation of the methodological quality of the included studies, informa-
tion about authors/year, study design, participants’ demographics (sex,
mean age and SD) and disease status (mean and SD of FEV1/FVC) were
collected.
Quality themes and principles relevant to the topic were evaluated
according to the QUADAS-2 (Quality Assessment of Diagnostic Accuracy
Studies, revised) tool [21]: four domains (patient selection, index test,
reference standard, flow and timing) were assessed in terms of risk of
bias and concerns regarding applicability. Although such tool is primar-
ily focused upon studies of healthcare intervention, in particular ran-
domized control trials, we adapted QUADAS-2 requirements to fit the
specificity of observational cross-sectional studies conducted in gait lab-
oratories.
3. Results
3.1. Electronic literature search results
A total of 1169 records were retrieved from the electronic databases.
Eleven additional items were found through screening of reference lists
and review articles, and two belonged to the Authors’ personal collec-
tion. After removing 225 duplicates, titles and abstracts screening led
to exclude 896 papers and conference proceedings. Despite among the
latter two potentially relevant studies were identified, they were prelim-
inary studies anticipating full-papers of the same group [22,23]. Of the
remaining 61 articles, 54 were removed since they did not meet inclu-
sion criteria. Most of them compared the outcomes of 6MWT or 4MWT
(walking distance or speed) to clinical or physiological measures. Seven
papers were included in the review. The selection process is summarised
in Fig. 1.
3.2. Description of the included studies
All the included papers were observational cross-sectional studies
published from 2011 to 2017 and assessing a cohort of patients with
COPD and a control group, with the exception of [24], who com-
pared their results to a previously published normative database (Table
1). The sample size of patients with COPD ranged from 14 to 196
(mean age range: 64–75 years). Three papers [22,23,25] relied on tra-
ditional optical motion capture combined with force platforms to col-
lect full-body three-dimensional kinematics and kinetics (joint angles,
moments and powers); in the remaining papers, spatiotemporal para-
meters and dependent variables were obtained by means of electronic
walkways [12,26], video analysis [24] or inertial units [27]. All stud-
ies required participants to walk at their self-selected walking speed, ei-
ther over ground (6MWT) or on a treadmill. Only Yentes et al. (2017)
analysed two walking conditions at ±20% of self-selected speed.
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Fig. 1. Articles search process flowchart.
3.3. Quality of the included studies
A global picture of the quality of the included studies is reported in
Fig. 2. The experimental procedures (flow and timing, tests) were on
average fairly good, showing a low risk of bias in 71% of studies. Con-
versely, patients’ selection was deemed with a high risk of bias in 5 out
of 7 studies, with high concerns on the applicability of the results in 2
out of 7 papers. This was mainly due to patients’ characteristics: first,
the sample size was larger than 20 only in 3 studies. Second, the gender
distribution in the COPD groups was not homogeneous and, with few
exceptions, unmatched with the control group.
3.4. Summary of evidence
The main significant gait differences between patients with COPD
and control groups assessed in the reviewed studies are listed in Table
2. Lower walking speed was reported in patients with COPD by Nantsu-
pawat et al. [24]. Yentes et al. [23] noticed a consistent (−15%) whilst
not significant (p=0.06, t-test) reduction in gait speed. McCamley et al.
[25] and Yentes et al. [22] did not find significant differences between
groups, since they matched patients and controls in terms of walking
speed, either a-priori or by covariate analysis. In addition, patients with
COPD generally tend to reduce their stride (and step) length and ca-
dence [12,23,26,27].
Variability measures were provided by two papers [23,27]. When
evaluated as standard deviation, step width variability was reduced in
patients with COPD, and step time variability was increased [23]. A
lower autocorrelation coefficient, meaning an increased variability over
time, was computed on step width [27].
Only two studies to date presented joint angles and moments curves,
and just small abnormalities were reported. While McCamley et al. [25]
did not find any significant difference, Yentes et al. [22] observed an
altered pattern at the ankle level, after correcting for covariates of age,
gender and smoking history. In particular, they measured an increased
peak ankle power absorption at mid-stance and a lack of increase in
peak ankle dorsiflexion moment in fatigued conditions with respect
to controls. Annegarn et al. [27] combined accelerometer data into a
unique synthetic variable, called ‘walking intensity’, that was computed
from the integral of the modulus of the output of an accelerometer
placed at the trunk level. Walking intensity was lower in COPD patients
than in controls, and proved to be strongly correlated with the distance
covered in the 6MWT, and moderately correlated with FEV1.
4. Discussion
The gait abnormalities that were more frequently identified in pa-
tients with COPD were reduced step length and cadence [23,24,26,27],
and altered variability of spatiotemporal parameters [23,27]. Subtle bio-
mechanical changes were also reported at the ankle level in terms of
joint powers and moments [22].
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Table 1
Key features of the examined papers. Participants demographics, laboratory equipment, trial specifications and most relevant findings are reported.
Reference
Author and
year Country
Patients: n (sex), age,
disease status
Controls: n
(sex), age,
characteristics
Testing
device Trial Variables
[26] Rutkowski et
al., 2011
Poland 33 (6F), 65.7±10.4 y 48 (35F),
58.7±11.8 y
Electronic
walkway
system
6MWT Spatiotemporal
parameters
Clinically diagnosed for
COPD
[27] Annegarn et
al., 2012
The
Netherlands
79 (31F), 64.3±8.9 y, 24 (10F),
63.7±5.9 y,
Inertial
units
6MWT Spatiotemporal
parameters
FEV1/FVC: 0.54±0.19 FEV1/FVC:
1.25±0.21
Trunk acceleration and
walking intensity
GOLD 1: n=8
GOLD 2: n=36
GOLD 3: n=28
GOLD 4: n=7
[22] Yentes et al.,
2015
USA 17 (6F), 63.8±8.6 y, 21 (11F),
65.3±7.7 y,
Optical
motion
capture
and GRF
10-m
pathway
at self-
selected
speed,
before
and after
fatigue
protocol
Spatiotemporal
parameters
FEV1/FVC: 0.51±0.02 FEV1/FVC:
0.74±0.04
Joint angles, moments
and powers
[12] Lahousse et
al., 2015
The
Netherlands
196 (76F), 75.0±5.5 y, 898 (483F),
74.2±5.2 y,
Electronic
walkway
system
6-m
pathway
at self-
selected
speed
Gait domains obtained
from spatiotemporal
parameters
FEV1/FVC=0.63±0.06 FEV1/FVC:
0.79±0.05
GOLD 1: 96
GOLD 2–3: 100
[24] Nantsupawat
et al., 2015
USA 14 (6F), 69.7±6.0 y, 296 (186F),
79.0±5.0 y,
from normative
study⁠a
Video
analysis
10-m
pathway
at self-
selected
speed
Spatiotemporal
parameters
FEV1/FVC: 0.48±0.05
GOLD 1: 0
GOLD 2: 2
GOLD 3: 6
GOLD 4: 6
[25] McCamley et
al., 2017
USA 16 (? F), 63.8±8.8 y, 20 (? F),
66.4±6.9 y,
Optical
motion
capture
and GRF
10-m
pathway
at self-
selected
speed
Joint angles, moments
and powers
FEV1/FVC<0.7 FEV1/FVC>0.9
[23] Yentes et al.,
2017
USA 20 (4 F), 63.6±9.7 y, 20 (11 F),
62.5±8.2 y,
Optical
motion
capture
3-min
walking
on a
treadmill
at self-
selected
and
±20% of
self-
selected
speed
Amount (standard
deviation and coefficient
of variation) and
temporal structure of
variability (sample
entropy) related to
spatiotemporal
parameters
FEV1/FVC: 0.52±0.12 FEV1/FVC:
0.79±0.06
F: females; 6MWT: 6-min Walking Test; GOLD: Global Initiative for Chronic Obstructive Lung Disease, disease stage: 1, mild; 2, moderate; 3, severe; 4, very severe [3]; GRF: Ground
Reaction Force.
a Mayo Clinic Study of Aging [49].
4.1. Gait characteristics of patients with COPD
4.1.1. Spatiotemporal parameters
There is a general consensus on the fact that patients with COPD
walk slower in tests like the 6MWT than healthy age-matched individu
als [19,28,29]. However, as speed is responsible of considerable changes
in gait patterns [30], to exclude a possible confounding factor and to
better identify COPD-specific characteristics, gait should be evaluated at
similar speeds as done in [22,25].
A general pattern in patient with COPD is the reduction of stride
length and cadence [12,23,26,27]. Lahousse et al. revealed that ca
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Fig. 2. Summary of the QUADAS-2 results.
dence and speed were positively related with FEV1/FVC, and that
their deterioration was associated with the degree of airflow limitation,
symptoms and frequency of exacerbations [12]. Abnormalities in stride
time were also observed during 6MWT, partially explaining the lower
distance covered by patients with COPD in the test [27]. On one hand,
increased stride time has been associated to the history of falls: com-
bined with a prolonged double support time [24], it can be a strategy
to increase stability and reduce the risk of falls [23,24]. Further, fall-
ers with COPD showed a significantly lower speed and cadence than
fallers without COPD [12]. On the other hand, taking slower steps can
be the effect of an altered mechanism aimed at coping with impaired
walking endurance due to the lack of oxygen supply [12,26]. This might
decrease the oxygen requirements of leg muscles and allow for longer
walking distance in individuals with impaired lung function [12].
In fatigued conditions, Yentes and collaborators [22] observed that
stride length was longer in patients with COPD (possibly due to in-
creased tibialis anterior fatigability), and step width decreased with fa-
tigue instead of increasing as in the healthy controls—the Authors as-
cribed opposite results obtained from previous observations to a differ-
ent approach in computing step width [23]. Changes in step width were
associated to fall risk [31,32]. Therefore, this pattern could be a sign of
instability due to a smaller base of support, and can be explained by a
reduced control of balance in the medio-lateral direction due to greater
center of pressure and hip angular displacements [7,22,23,33].
4.1.2. Variability
Mediolateral variability in gait, largely due to lateral foot place-
ment, was reported as an active control strategy to compensate for bal-
ance disturbances and maintain stability in the propulsive (anteropos-
terior) direction. To compensate for balance disturbances during walk-
ing, an adjustment of step width is necessary (largely through lateral
foot placement), resulting in an increased variability of the walking
Table 2
significant walking abnormalities identified in the reviewed studies between patients with
COPD and healthy controls.
Domain
Qualitative
gait feature
(COPD vs.
controls)
Quantitative
results and
REFERENCES
(COPD vs.
controls)
Rationale and/
or
consequences
Spatiotemporal
parameters
Slower
walking
speed
1.09 vs.
1.17m/s,
outside 95%
confidence
interval [24]
Reflects
respiratory
limitations
associated with
muscle wasting,
reduced muscle
strength,
reduced
physical
activity and
loss of
conditioning.
Reduced
step width
(in fatigued
conditions)
0.09 vs 0.11m,
p<0.05 [23]
Brings to
instability due
to a smaller
base of support.
Increased
step/stride
time or
lower stride
cadence
Stride time,
0.49 vs. 0.48s,
p<0.05 [26]
It is associated
to fall history.
Encapsulated
in a synthetic
variable
(Rhythm),
p<0.05 [12]
Reflects
changes in
performance
capacity.
Cadence 0.95
vs. 1.10 stride/
s, p<0.05
[27]
Evidence of an
altered walking
pattern.
Step time 0.8
vs. 0.7s,
p<0.05 [23]
Adaptation
mechanism to
cope with
impaired
walking
endurance due
to reduced
oxygen supply.
Stride length Stride length,
0.75 vs. 0.77m,
p<0.05 [26]
Reflects
changes in
performance
capacity
Strategy to
increase
stability and
reduce risk of
fall
Increased
double
support time
0.36 vs. 0.31,
outside 95%
confidence
interval [24]
Strategy to
increase
stability and
reduce risk of
fall
Variability Higher step
time SD
0.04 vs. 0.03s,
p<0.05 [23]
Accounts for
the increased
risk of falling in
COPD.
Reduced
step width
SD
0.014 vs.
0.018, p<0.05
[23]
Accounts for
the increased
risk of falling in
COPD.
Reflects
impaired
balance control
in the
mediolateral
direction.
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Table 2 (Continued)
Domain
Qualitative
gait feature
(COPD vs.
controls)
Quantitative
results and
REFERENCES
(COPD vs.
controls)
Rationale and/
or
consequences
Higher
mediolateral
variability
Autocorrelation
coefficient
63.2% vs.
73.7%,
p<0.05 [27]
Active control
strategy to
compensate for
balance
disturbances
and maintain
stability in the
anteroposterior
direction.
Reflects higher
balance
disturbances
while walking.
Kinematics
and kinetics
Reduced
walking
intensity
8658 vs.
14,054 counts/
min, p<0.05
[27]
Associated to
6MWD results.
Possibility for
routine
assessment of
exercise
performance in
a home-based
setting.
Increase
peak ankle
power
absorption
at mid-
stance
∼2 vs. ∼1.5W/
kg, p<0.05
[22]
Reflects
problems in
controlling the
foot shortly
after heel-strike
(tibialis
anterior
weakness).
Lack of
increase in
peak
dorsiflexion
moment in
fatigued
condition
pattern [27]. Step width variability is the dependent variable associated
with fall risk, prediction of falls and fear of falling in older adults, rather
than just a mean change in step width [31,34].
In patients with COPD, recent investigations about step width vari-
ability reported reductions in both autocorrelation of step width [27],
suggesting an increased mediolateral variability, and step width stan-
dard deviation [23]. While these may appear as contrasting results, they
were in fact complementary. The first (autocorrelation) is about the
structure of the movement over time, while the latter (standard devia-
tion) refers to spatiotemporal parameters variability; they both support
the idea of a general inability to compensate for instability, thus pre-
disposing an individual to falls [36]. Since both increases and decreases
in step width variability are related to a history of falls in older adults
[34,36], the assessed contributions were consistent in linking an alter-
ation in walking variability (particularly in the mediolateral direction)
to an augmented risk of falling for patients with COPD. Further, walk-
ing variability is a clinically relevant variable in these patients, since it
significantly contributes to the prediction of the distance in the 6MWT
[27].
4.1.3. Kinematics and kinetics
A single study observed an increased peak power absorption during
midstance measured at the ankle level, together with a lack of increase
in peak ankle dorsiflexion moment under fatigued conditions [22].
Combined with the longer stride lengths noted in the same no-rest con
dition, this can be motivated by a problem in controlling the foot shortly
after heel-strike due to an early tibialis anterior fatigability [22].
4.2. Source of gait abnormalities in COPD
Irregular walking patterns and the decline of physical and ambula-
tory activity in patients with COPD can be caused by both the chronic
respiratory limitations and the systemic comorbidities of the disease.
COPD limits ventilation causing dynamic hyperinflation when expira-
tory time is not sufficient to enable lung emptying [37,38]. This imposes
constraints on tidal volume, leading to dyspnoea, the most common ac-
tivity-limiting symptom of COPD. Since the level of dyspnoea is corre-
lated to the intensity of the activity performed, people with COPD tend
to progressively reduce their physical activity, even to less than 15-min
per day [11].
A systemic inflammation was observed in patients with stable COPD
as an increased number of leukocytes, acute phase response proteins
(C-reactive proteins and fibrinogen) and cytokines (particularly the tu-
mour necrosis factor (TNF-); the systemic inflammation is involved in
the pathogenesis of the majority of systemic effects of COPD [2], includ-
ing skeletal muscle dysfunction and osteoporosis [3]. Several structural
adaptations in muscles develop with COPD, in particular at lower limb
level [5]: sarcopenia (loss of muscle cells) and atrophy, decreased cap-
illary and mitochondrial density and a shift from slow-twitch (type-I)
towards fast-twitch (type-II) anaerobic muscle fibers, resulting in re-
duced oxidative and increased glycolytic capacity [3,13]. This shift sug-
gests decreased endurance and a higher susceptibility to muscle fatigue
and weakness [4,39,40]. Interestingly, the fiber shift in patients with
COPD is opposite to the shift naturally induced by age [13]. Mechani-
cal unloading due to physical inactivity contributes to peripheral mus-
cle abnormalities and dysfunction. Muscle weakness in COPD has been
reported primarily in thigh musculature (quadriceps, in both men and
women [41]), and more recently documented in the ankle dorsiflexors
and plantarflexors [42,43]. Taken together, these abnormalities indicate
an overall decline in both the contractile and oxidative capacity of lower
limbs muscles in patients with COPD [11].
Strong correlations exist among fall incidence, sensorimotor postural
deficiencies and lower limb muscle weakness. Muscle strength is an es-
sential factor in maintaining postural control and minimizing postural
sway, both of which are crucial in preventing older adults from falling
[44]. Patients with COPD present a deficit of proprioceptive control and
a higher body oscillation frequency [7]. Impaired balance and slower
reaction times in response to perturbations increase the risk for falls and
important complications, such as fractures [8,24]. It was suggested that
increased mediolateral body oscillations in patients with COPD may be
due to thoracoabdominal asynchrony with inadequate contribution to
the thorax compartment to tidal volume that eases postural sway [7].
Gait deficits observed in patients with COPD were similar to those
found in patients with an elevated fall risk [6]. The evidence provided
in the current review partly supports this line, since gait variability
impairments were observed by different Authors [23,27]. The respira-
tory symptoms and neuromuscular deficits of the disease reduce both
function and mobility and would suggest strong changes of the walk-
ing function, that in COPD was associated with limp, shuttle or other
walking abnormalities [45]. Contrary to this hypothesis, patients with
COPD demonstrated minimal significant differences in biomechanical
gait analysis, gathered results were not coincident, and there were stud-
ies [22,24,25] reporting qualitatively normal gait and balance in similar
populations. Thus, the results emerging from the existing literature do
not allow to draw conclusive traits of the gait patterns in patients with
COPD (Table 2).
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4.3. Article quality
The paucity of studies on the topic and the average poor method-
ological quality in the recruitment of cohorts were the main reasons for
the uncertainty and sometimes ambiguity of the results. In particular,
four major flaws emerged: small sample size, gender and disease status
pooling, speed mismatches.
About sample size, van der Linde et al. [46] suggested that the num-
ber of independent variables (K) can be considered adequate if the ra-
tio K:n, where n is the sample size, exceeds 1:10. Over 70% of the ar-
ticles that we included in the review did not meet such requirement
(n=36.8±18.2 patients with COPD, range 14–71, Table 1). A small
sample size reduces the ability to validate the hypothesis, increases the
risk of type-II error and reduces the discriminating capacity of a para-
meter and in turn the relevance of the results.
The extent to which the disease severity can contribute to mechan-
ical impairments in patients with COPD is still debated. When COPD
becomes aggravated, patients suffer from deteriorated functional status
and limitations in daily life [28]: physical activity is reduced in patients
with GOLD [3] stage 1, and this reduction further worsens with dis-
ease severity, being the patients with COPD GOLD stage 4 very inactive
[13]. A significant association between COPD severity status and walk-
ing and abnormalities was also observed in self-reported reports [45].
This is consistent with the findings by Yentes et al. [22], who noticed
larger step width just in COPD GOLD 3 and 4 stages. In sum, deficits
in functional balance, coordination, and mobility were associated with
disease severity or with differences in activity levels [7,28], and the se-
vere GOLD categories were associated with worse global gait and pace
characteristics [27]. Thus, combining data from patients belonging to
different stages of the disease could have had the effect of weakening
results and masking possible relevant differences between stages of the
disease and/or healthy controls. The absence of a clear trend in the re-
viewed studies can therefore be related to the inherent heterogeneity
in which COPD presents itself clinically [22]. Indeed, different pheno-
types of the disease have been recently identified based on demograph-
ics (age, gender or smoking history), physiological (decline in FEV1/
FVC), radiographic or imaging factors (structural abnormalities), acute
exacerbations of COPD, degree of systemic inflammation and the pres-
ence of comorbidities (cardiovascular disease, metabolic syndrome, os-
teoporosis, diabetes, depression) [22,47]. It is possible that a subset of
patients with COPD may manifest differences that have not been ob-
served in the larger groups [22].
Gender effect was took into account only by Yentes et al. [22]. Till
still debated in the scientific community, in principle one cannot be un-
aware that sex-specific differences were observed in kinematic and ki-
netic gait patterns among groups of elderly individuals [48,49]. Since
such differences concern spatiotemporal parameters (and related vari-
ability) that were found to be sensitive to the presence of COPD, com-
paring severely unbalanced cohorts without correcting for the gender
effect might have played an additional role in increasing the sources of
bias.
Lastly, walking speed is known to greatly influence gait mechanics
[30]. Therefore, results of studies that do not match groups for speed
should be regarded with caution. Since a reduced walking velocity is in-
herently a characteristic of patients with COPD [24], findings could be
provided considering speed as a covariate.
5. Conclusions and recommendations for future research
This review provided evidence that COPD is likely to alter patients’
spatiotemporal gait patterns as compared to healthy age-matched con-
trols. In particular, COPD was related with taking slower steps and
with reduced cadence [12,23,24,26,27], increased double support time
[24] and altered gait variability [23,27]. Kinetic abnormalities have
been also observed at the ankle level, with a reduction in push-off
force following a fatigued condition [22]. However, there is presently
a paucity of evidence that identifies a convincing mechanistic link be-
tween such gait impairments and falls in patients with COPD.
Overall, due to methodological inconsistencies, the reviewed stud-
ies highlighted trends of future investigations rather than crucial dif-
ferences among the gait patterns of patients with COPD and those of
healthy individuals. Two main directions of research emerged: stricter
cohorts characterization and longitudinal studies. First, walking abnor-
malities could be significantly associated with COPD severity [45]. Since
all the studies defined COPD by spirometry alone and not by the com-
bination of symptoms and spirometry [3], it is advisable that future
researches would investigate biomechanical abnormalities in different
COPD phenotypes, distinguishing between disease severity and patients’
gender. In that, the heterogeneity of manifestation of COPD in the sam-
ples analysed by the current literature is the main limitation that future
research is called to fill. Second, future studies might include repeated
measures to investigate the effect of a pulmonary rehabilitation program
on walking patterns in patients with COPD [27].
Gait instability is a major fall-risk factor in patients with COPD [23],
and walking is one of the most frequent dynamic activities of daily liv-
ing [50]. To allow preventive strategies to become effective, it is cru-
cial to identify individuals with unstable gait. Quantitative gait analysis
can reveal abnormal gait parameters that are not apparent to visual in-
spection or identified by gait speed. The assessment of gait variability
provides a viable option for the evaluation of stability and to determine
whether mechanical limitations are associated with the severity of the
disease [45,50]. Lastly, the measurement of joint moments can provide
insight into the net response of all muscle groups in the lower limbs, re-
vealing crucial COPD-related adaptations [22]. In turn, this knowledge
may aid in identifying proper intervention strategies to prevent falling
in patients with COPD [12].
Funding
This project was supported by an unconditioned Research Grant sup-
plied from the “Filippo Serpero Foundation”, Milan, Italy.
Conflict of interest statement
All authors have no financial and personal relationships with other
people or organizations that could inappropriately influence their work.
The author confirms that there are no known conflicts of interest regard-
ing the work described in the current manuscript.
Uncited reference
[35].
References
[1] D. Adeloye, S. Chua, C. Lee, C. Basquill, A. Papana, E. Theodoratou, H. Nair, D. Ga-
sevic, D. Sridhar, H. Campbell, K.Y. Chan, A. Sheikh, I. Rudan, Global and regional
estimates of COPD prevalence: systematic review and meta–analysis, J. Glob.
Health 5 (2015).
[2] A. Agusti, A. Agustí, Systemic effects of chronic obstructive pulmonary disease:
what we know and what we don’t know (but should), Proc. Am. Thorac. Soc.
4 (2007) 522–525.
[3] C.F. Vogelmeier, G.J. Criner, F.J. Martinez, A. Anzueto, P.J. Barnes, J. Bourbeau,
B.R. Celli, R. Chen, M. Decramer, L.M. Fabbri, P. Frith, D.M.G. Halpin, M.V. López
Varela, M. Nishimura, N. Roche, R. Rodriguez-Roisin, D.D. Sin, D. Singh, R. Stock-
ley, J. Vestbo, J.A. Wedzicha, A. Agustí, Global strategy for the diagnosis manage-
ment, and prevention of chronic obstructive lung disease 2017 report. GOLD exec-
utive summary, Am. J. Respir. Crit. Care Med. 195 (2017) 557–582.
[4] Y. Nussbaumer-Ochsner, K.F. Rabe, Systemic manifestations of COPD, Chest
139 (2011) 165–173.
7
UN
CO
RR
EC
TE
D
PR
OO
F
M. Zago et al. Gait & Posture xxx (2018) xxx-xxx
[5] S. Bernard, P. LeBlanc, F. Whittom, G. Carrier, J. Jobin, R. Belleau, F. Maltais, Pe-
ripheral muscle weakness in patients with chronic obstructive pulmonary disease,
Am. J. Respir. Crit. Care Med. 158 (1998) 629–634.
[6] M.K. Beauchamp, D. Brooks, R.S. Goldstein, Deficits in postural control in individu-
als with COPD – emerging evidence for an important secondary impairment, Multi-
discip. Respir. Med. 5 (2010) 417–421.
[7] E.F. Porto, A.A.M. Castro, V.G.S. Schmidt, H.M. Rabelo, C. Kumpel, O.A. Nasci-
mento, J.R. Jardim, Postural control in chronic obstructive pulmonary disease: a
systematic review, Int. J. Chron. Obstruct. Pulmon. Dis. 10 (2015) 1233–1239.
[8] M. Roig, J.J. Eng, D.L. MacIntyre, J.D. Road, W.D. Reid, Deficits in muscle strength
mass, quality, and mobility in people with chronic obstructive pulmonary disease,
J. Cardiopulm. Rehabil. Prev. 31 (2010) 120–124.
[9] S.J. Butcher, J.M. Meshke, M.S. Sheppard, Reductions in functional balance, coor-
dination, and mobility measures among patients with stable chronic obstructive
pulmonary disease, J. Cardiopulm. Rehabil. 24 (2004) 274–280.
[10] M.D. Eisner, P.D. Blanc, E.H. Yelin, S. Sidney, P.P. Katz, L. Ackerson, P. Lathon, I.
Tolstykh, T. Omachi, N. Byl, C. Iribarren, COPD as a systemic disease: impact on
physical functional limitations, Am. J. Med. 121 (2008) 789–796.
[11] M. Roig, J.J. Eng, J.D. Road, W.D. Reid, Falls in patients with chronic obstructive
pulmonary disease: a call for further research, Respir. Med. 103 (2009)
1257–1269.
[12] L. Lahousse, V.J.A. Verlinden, J.N. Van Der Geest, G.F. Joos, A. Hofman, B.H.C.
Stricker, G.G. Brusselle, M.A. Ikram, J.N. Van Der Geest, G.F. Joos, A. Hofman,
B.H.C. Stricker, G.G. Brusselle, M.A. Ikram, Gait patterns in COPD: the Rotterdam
study, Eur. Respir. J. 46 (2015) 88–95.
[13] N. Cielen, K. Maes, G. Gayan-Ramirez, Musculoskeletal disorders in chronic ob-
structive pulmonary disease, Biomed Res. Int. 2014 (2014).
[14] P. Kannus, H. Sievänen, M. Palvanen, T. Järvinen, J. Parkkari, Prevention of falls
and consequent injuries in elderly people, Lancet 366 (2005) 1885–1893.
[15] A. Clegg, J. Young, S. Iliffe, M.O. Rikkert, K. Rockwood, Frailty in elderly people,
Lancet 381 (2013) 752–762.
[16] S.A. Bridenbaugh, R.W. Kressig, Laboratory review: the role of gait analysis in se-
niors’ mobility and fall prevention, Gerontology 57 (2011) 256–264.
[17] J. Verghese, R. Holtzer, R.B. Lipton, C. Wang, Quantitative gait markers and inci-
dent fall risk in older adults, J. Gerontol. Ser. A Biol. Sci. Med. Sci. 64 (2009)
896–901.
[18] T. Ringbaek, G. Martinez, E. Brøndum, J. Thøgersen, M. Morgan, P. Lange, Shuttle
walking test as predictor of survival in chronic obstructive pulmonary disease pa-
tients enrolled in a rehabilitation program, J. Cardiopulm. Rehabil. Prev.
30 (2010) 409–414.
[19] C. Karpman, R. Benzo, Gait speed as a measure of functional status in COPD pa-
tients, Int. J. COPD 9 (2014) 1315–1320.
[20] C. Garvey, A.M. Boylan, D.L. Miller, A.E. Holland, S.J. Singh, M.A. Spruit, K.C. Wil-
son, C.C. Thomson, Field walking tests in chronic respiratory disease, Ann. Am.
Thorac. Soc. 12 (2015) 446–447.
[21] P. Whiting, A. Rutjes, M. Westwood, S. Mallett, J. Deeks, J. Reitsma, M.M.
Leeflang, J.A. Sterne, P. Bossuyt, QUADAS-2: a revised tool for the quality assess-
ment of diagnostic accuracy studies, Ann. Intern. Med. 155 (2011) 529–536.
[22] J.M. Yentes, K.K. Schmid, D. Blanke, D.J. Romberger, S.I. Rennard, N. Stergiou,
Gait mechanics in patients with chronic obstructive pulmonary disease, Respir.
Res. 16 (2015) 31.
[23] J.M. Yentes, S.I. Rennard, K.K. Schmid, D. Blanke, N. Stergiou, Patients with COPD
walk with altered step time and step width variability as compared to healthy con-
trols, Ann. Am. Thorac. Soc. (2017), AnnalsATS.201607-547OC.
[24] N. Nantsupawat, P. Lane, O. Siangpraipunt, S. Gadwala, K. Nugent, Gait character-
istics in patients with chronic obstructive pulmonary disease, J. Prim. Care Com-
munity Health 6 (2015) 222–226.
[25] J.D. McCamley, E.J. Pisciotta, J.M. Yentes, S.R. Wurdeman, S.I. Rennard, I.I.
Pipinos, J.M. Johanning, S.A. Myers, Gait deficiencies associated with peripheral
artery disease are different than chronic obstructive pulmonary disease, Gait Pos-
ture 57 (2017) 258–264.
[26] S. Rutkowski, A. Rutkowska, J. Łuniewski, J. Szczegielniak, Gait analysis of pa-
tients with chronic obstructive pulmonary disease, Fizjoterapia Pol. 4 (2011)
24–33.
[27] J. Annegarn, M.A. Spruit, H.H.C.M. Savelberg, P.J.B. Willems, C. van de Bool,
A.M.W.J. Schols, E.F.M. Wouters, K. Meijer, C. Van De Bool, A.M.W.J. Schols,
E.F.M. Wouters, K. Meijer, Differences in walking pattern during 6-min walk test
between patients with COPD and healthy subjects, PLoS One 7 (2012) 3–8.
[28] Y. Liu, H. Li, N. Ding, N. Wang, D. Wen, Functional status assessment of patients
with COPD, Medicine (Baltimore) 95 (2016) e3672.
[29] C. Karpman, Z.S. Depew, N.K. Lebrasseur, P.J. Novotny, R.P. Benzo, Determinants
of gait speed in COPD, Chest 146 (2014) 104–110.
[30] J. Perry, J.M. Burnfield, Gait Analysis: Normal and Pathological Function, 2nd ed.,
SLACK Incorporated, Thorofare, New Jersey, 2010.
[31] J.C. Dean, N.B. Alexander, A.D. Kuo, The effect of lateral stabilization on walking
in young and old adults, IEEE Trans. Biomed. Eng. 54 (2007) 1919–1926.
[32] M.A. Schrager, V.E. Kelly, R. Price, L. Ferrucci, A. Shumway-Cook, The effects of
age on medio-lateral stability during normal and narrow base walking, Gait Pos-
ture 28 (2008) 466–471.
[33] M.D. Smith, A.T. Chang, H.E. Seale, J.R. Walsh, P.W. Hodges, Balance is impaired
in people with chronic obstructive pulmonary disease, Gait Posture 31 (2010)
456–460.
[34] J.S. Brach, J.E. Berlin, J.M. VanSwearingen, A.B. Newman, S. a Studenski, Too
much or too little step width variability is associated with a fall history in older
persons who walk at or near normal gait speed, J. Neuroeng. Rehabil. 2 (2005) 21.
[35] J.M. Yentes, S.I. Rennard, K.K. Schmid, D. Blanke, N. Stergiou, Patients with
chronic obstructive pulmonary disease walk with altered step time and step width
variability as compared with healthy control subjects, Ann. Am. Thorac. Soc.
14 (2017) 858–866.
[36] O. Beauchet, G. Allali, C. Annweiler, S. Bridenbaugh, F. Assal, R.W. Kressig, F.R.
Herrmann, Gait variability among healthy adults: low and high stride-to-stride
variability are both a reflection of gait stability, Gerontology55 (2009) 702–706.
[37] D.E. O’Donnell, J. Ora, K.A. Webb, P. Laveneziana, D. Jensen, Mechanisms of ac-
tivity-related dyspnea in pulmonary diseases, Respir. Physiol. Neurobiol.
167 (2009) 116–132.
[38] N.R. MacIntyre, Mechanisms of functional loss in patients with chronic lung dis-
ease, Respir. Care 53 (2008) 1177–1184.
[39] H.R. Gosker, H. van Mameren, P.J. van Dijk, M.P.K.J. Engelen, G.J. van der Vusse,
E.F.M. Wouters, A.M.W.J. Schols, Skeletal muscle fibre-type shifting and metabolic
profile in patients with chronic obstructive pulmonary disease, Eur. Respir. J.
19 (2002) 617–625.
[40] M.J. Mador, O. Deniz, A. Aggarwal, T.J. Kufel, Quadriceps fatigability after single
muscle exercise in patients with chronic obstructive pulmonary disease, Am. J.
Respir. Crit. Care Med. 168 (2003) 102–108.
[41] H.R. Gosker, M.K. Hesselink, H. Duimel, K.A. Ward, A.M. Schols, Reduced mito-
chondrial density in the vastus lateralis muscle of patients with COPD, Eur. Respir.
J. 30 (2007) 73–79.
[42] P. Gagnon, F. Maltais, L. Bouyer, F. Ribeiro, V. Coats, C. Brouillard, M. Noël, M.
Rousseau-Gagnon, D. Saey, Distal leg muscle function in patients with COPD,
COPD 10 (2013) 235–242.
[43] M. Maddocks, M. Jones, T. Snell, B. Connolly, S. de Wolf-Linder, J. Moxham, G.F.
Rafferty, Ankle dorsiflexor muscle size, composition and force with ageing and
chronic obstructive pulmonary disease, Exp. Physiol. 99 (2014) 1078–1088.
[44] J.D. Moreland, J.A. Richardson, C.H. Goldsmith, C.M. Clase, Muscle weakness and
falls in older adults: a systematic review and meta-analysis, J. Am. Geriatr. Soc.
52 (2004) 1121–1129.
[45] J.M. Yentes, H. Sayles, J. Meza, D.M. Mannino, S.I. Rennard, N. Stergiou, Walking
abnormalities are associated with COPD: an investigation of the NHANES III
dataset, Respir. Med. 105 (2011) 80–87.
[46] H. van der Linde, C.J. Hofstad, A.C.H. Geurts, K. Postema, J.H.B. Geertzen, J. van
Limbeek, A systematic literature review of the effect of different prosthetic compo-
nents on human functioning with a lower-limb prosthesis, J. Rehabil. Res. Dev.
41 (2004) 555–570.
[47] X. Chen, X. Xu, F. Xiao, Heterogeneity of chronic obstructive pulmonary disease:
from phenotype to genotype, Front. Med. 7 (2013) 425–432.
[48] S. Ko, M.I. Tolea, J.M. Hausdorff, L. Ferrucci, Sex-specific differences in gait pat-
terns of healthy older adults: results from the Baltimore longitudinal study of
aging, J. Biomech. 44 (2011) 1974–1979.
[49] J.H. Hollman, E.M. McDade, R.C. Petersen, Normative spatiotemporal gait parame-
ters in older adults, Gait Posture 34 (2011) 111–118.
[50] D. Hamacher, N.B. Singh, J.H. Van Dieen, M.O. Heller, W.R. Taylor, Kinematic
measures for assessing gait stability in elderly individuals: a systematic review, J.
R. Soc. Interface 8 (2011) 1682–1698.
8
